Hosted on MSN2mon
Fate stock closes 12% higher after soaring 73% on drug data (update)
F ate Therapeutics (NASDAQ:FATE) stock closed 12% higher Monday after soaring as much as 73% on news that the first patient in the company's Phase 1 Autoimmunity study for its CAR T-cell therapy ...
ETF Daily News11d
Cantor Fitzgerald Predicts FATE FY2025 Earnings
Get Fate Therapeutics alerts: Other analysts also recently issued reports about the stock. Bank of America raised shares of Fate Therapeutics from an “underperform” rating to a “neutral ...